ARVINAS, INC.
About ARVINAS, INC.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $262.6M
- Net income
- -$80.8M
- Total assets
- $717.9M
- Market cap
- $478.7M
- Operating margin
- -511.5%
- Net margin
- -467.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $78.5M
- Operating expenses
- $480.0M
- Operating income
- -$401.5M
- Income tax
- $900.0K
- Net income
- -$367.3M
- EPS (basic)
- $-6.62
- EPS (diluted)
- $-6.62
Balance sheet
- Total assets
- $1.3B
- Current assets
- $1.3B
- Total liabilities
- $644.6M
- Current liabilities
- $257.1M
- Shareholders’ equity
- $660.0M
Cash flow
- Operating cash flow
- -$347.8M
- Investing cash flow
- $203.5M
- Financing cash flow
- $374.7M
- Net cash flow
- $230.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $478.7M
- EPS (diluted)
- $-6.62
- Shares outstanding
- 67.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 27, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $80.8M in FY2025.
- Revenue grew 83% from FY2019 to FY2023.
- Trading 48% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ARVINAS, INC..
Write a review
News about ARVINAS, INC.
News & sentiment via Polygon.io
